Content deleted Content added
Albertaont (talk | contribs) update |
Albertaont (talk | contribs) update to similar technologies |
||
Line 43:
{{COVID-19 pandemic sidebar}}
'''SCB-2019''' is a [[protein subunit]] [[COVID-19 vaccine]] candidate developed by Clover Biopharmaceuticals with an [[Immunologic adjuvant|adjuvant]] from Dynavax.<ref name=":0">{{Cite web|date=2021-06-30|title=Chinese biotech firm Clover signs deal to make millions of vaccines|url=https://www.scmp.com/news/china/science/article/3139352/chinese-biotech-firm-clover-signs-deal-make-millions-covid-19|access-date=2021-07-08|website=South China Morning Post|language=en}}</ref> The vaccine published positive Phase I results in [[The Lancet]]<ref name=":1">{{Cite journal|last=Richmond|first=Peter|last2=Hatchuel|first2=Lara|last3=Dong|first3=Min|last4=Ma|first4=Brenda|last5=Hu|first5=Branda|last6=Smolenov|first6=Igor|last7=Li|first7=Ping|last8=Liang|first8=Peng|last9=Han|first9=Htay Htay|last10=Liang|first10=Joshua|last11=Clemens|first11=Ralf|date=February 2021|title=Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext|journal=The Lancet|language=English|volume=397|issue=10275|pages=682–694|doi=10.1016/S0140-6736(21)00241-5|issn=0140-6736}}</ref> and completed enrollment of its Phase II/III trials in July 2021, with efficacy results expected to be announced by Q3 2021.<ref name=":2" /> SCB-2019 is being funded by [[Coalition for Epidemic Preparedness Innovations|CEPI]] as part of [[COVAX]]<ref name=":3">{{Cite web|title=From lab to potential jab: Clover’s COVID-19 vaccine story|url=https://cepi.net/news_cepi/from-lab-to-potential-jab-clovers-covid-19-vaccine-story/|access-date=2021-07-08|website=CEPI|language=en-US}}</ref> and has received advanced purchase orders from [[GAVI]] for 400 million doses.<ref name=":4">{{Cite web|title=Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX|url=https://www.gavi.org/news/media-room/gavi-signs-agreement-clover-biopharmaceuticals-supply-covax|access-date=2021-07-08|website=www.gavi.org|language=en}}</ref>
The vaccine employs similar technology to other protein subunit COVID-19 vaccines including [[Novavax COVID-19 vaccine|Novavax]], [[Abdala (vaccine)|Abdala]], and [[ZF2001]].<ref>{{Cite news|last=Zimmer|first=Carl|last2=Corum|first2=Jonathan|last3=Wee|first3=Sui-Lee|title=Coronavirus Vaccine Tracker|language=en-US|work=The New York Times|url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html|access-date=2021-07-08|issn=0362-4331}}</ref>
== Manufacturing ==
Line 52 ⟶ 54:
In June 2020, [[GAVI]] announced an agreement with Clover for the purchase of 64 million doses in 2021 and an additional 350 million doses in 2022.<ref name=":0" /><ref name=":4" />
SCB-2019 is funded by [[Coalition for Epidemic Preparedness Innovations|CEPI]] as part of the [[COVAX]]. By November 2020, CEPI had invested $328 million in developing the vaccine. If the vaccine was
In February 2021, Clover decided to proceed with the adjuvant from Dynavax for its upcoming Phase II/III trials over GlaxoSmithKline after evaluating scale-up manufacturing considerations.<ref name=":5">{{Cite news|last=Liu|first=Roxanne|date=2021-02-01|title=Clover ends COVID-19 vaccine partnership with GSK|language=en|work=Reuters|url=https://www.reuters.com/article/health-coronavirus-clover-gsk-idUSL1N2K70R6|access-date=2021-07-08}}</ref> Separately, CEPI provided $99 million funding to Dynavax to manufacture its adjuvant for COVID-19 vaccines.<ref name=":5" />
| |||